These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [Treatment of multiresistant Pseudomonas aeruginosa infection in cystic fibrosis: how to progress?]. Burgel PR; Kanaan R Rev Mal Respir; 2010 May; 27(5):411-3. PubMed ID: 20569871 [No Abstract] [Full Text] [Related]
10. Diversification of Pseudomonas aeruginosa within the cystic fibrosis lung and its effects on antibiotic resistance. Clark ST; Guttman DS; Hwang DM FEMS Microbiol Lett; 2018 Mar; 365(6):. PubMed ID: 29401362 [TBL] [Abstract][Full Text] [Related]
11. New antimicrobials in the management of cystic fibrosis. Høiby N J Antimicrob Chemother; 2002 Feb; 49(2):235-8. PubMed ID: 11815562 [No Abstract] [Full Text] [Related]
12. Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies. Hassett DJ; Korfhagen TR; Irvin RT; Schurr MJ; Sauer K; Lau GW; Sutton MD; Yu H; Hoiby N Expert Opin Ther Targets; 2010 Feb; 14(2):117-30. PubMed ID: 20055712 [TBL] [Abstract][Full Text] [Related]
13. Multi-resistant Pseudomonas aeruginosa ST235 in cystic fibrosis. Lee AC; Jones AL Paediatr Respir Rev; 2018 Jun; 27():18-20. PubMed ID: 29914746 [TBL] [Abstract][Full Text] [Related]
14. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277 [TBL] [Abstract][Full Text] [Related]
15. Cystic fibrosis pathogenesis and the role of biofilms in persistent infection. Costerton JW Trends Microbiol; 2001 Feb; 9(2):50-2. PubMed ID: 11173226 [TBL] [Abstract][Full Text] [Related]
16. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Pang Z; Raudonis R; Glick BR; Lin TJ; Cheng Z Biotechnol Adv; 2019; 37(1):177-192. PubMed ID: 30500353 [TBL] [Abstract][Full Text] [Related]
17. The Pseudomonas aeruginosa genome: how do we use it to develop strategies for the treatment of patients with cystic fibrosis and Pseudomonas infections? Erwin AL; VanDevanter DR Curr Opin Pulm Med; 2002 Nov; 8(6):547-51. PubMed ID: 12394165 [TBL] [Abstract][Full Text] [Related]
18. Influence of biofilm formation in the susceptibility of Pseudomonas aeruginosa from Brazilian patients with cystic fibrosis. Ferreira AG; Leão RS; Carvalho-Assef AP; Folescu TW; Barth AL; Marques EA APMIS; 2010 Aug; 118(8):606-12. PubMed ID: 20666742 [TBL] [Abstract][Full Text] [Related]
19. The role of the CFTR in susceptibility to Pseudomonas aeruginosa infections in cystic fibrosis. Goldberg JB; Pier GB Trends Microbiol; 2000 Nov; 8(11):514-20. PubMed ID: 11121762 [TBL] [Abstract][Full Text] [Related]
20. Small colony variants of Pseudomonas aeruginosa in chronic bacterial infection of the lung in cystic fibrosis. Evans TJ Future Microbiol; 2015; 10(2):231-9. PubMed ID: 25689535 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]